Deerfield Management Company L P 13F Portfolio

The biggest add is Genmab, where Deerfield boosts the stake by +178.8% and adds about $121.0M. That’s a clear statement: they want more exposure to a profitable, late‑stage antibody platform that still screens under‑owned versus mega‑cap oncology, and they’re willing to pay up with shares already modestly above their cost.

They also build size in a cluster of maturing clinical stories. IDEAYA is up +77.4% in shares and BioMarin +56.5%, both after being held for six quarters and sitting comfortably above cost. That is classic scaling behavior: initial thesis validated by data and regulatory progress, then capital gets concentrated.

On the metabolic/kidney side they open a new $106.8M position in Mineralys and expand Structure Therapeutics by +41.4%, plus incremental adds to Revolution Medicines and Pharmavaris. Together, these moves say Deerfield wants sustained exposure to chronic-disease franchises with long duration revenue — a counterweight to binary early-stage bets.

Even at the smaller end, they are pressing into names where they’re still underwater but like the setup. TYRA Biosciences, still down vs buy-in, is nearly doubled in size (+85.2%), suggesting they’re leaning into dislocated precision‑oncology assets they think the market misprices once the next data read hits.

The funding leg is straightforward: take money off the table where the original bet has worked. Cogent Biosciences is the biggest cash register, with the position cut -44.6% and about $156.3M freed up while still sitting roughly +283.0% over cost. Indivior follows the same script: a -46.8% reduction after a roughly +228.0% gain.

There’s also quiet profit-taking in liquid health-care services and tools. Centene is trimmed -17.2% despite being comfortably in the green, and Lantheus is shaved by -9.1% with a strong gain vs cost. Both look like partial de‑risking of more defensive, payer/diagnostics exposure to recycle into higher upside pipelines.

On the other side of the ledger, they’re not sentimental about losers. Inspire Medical is halved (-52.0%) with the position now well below their average entry, and Sionna is cut -29.8% while deeply underwater. Celcuity and Arrowhead also see mid‑teens trims. These look less like funding sources from strength and more like a deliberate cleanup of thesis drift — capital pulled from stories where the risk/reward no longer justifies patience.

At the top level, the bar chart will show almost nothing changed: health care inches from 98.49% to 98.52%, with Industrials (Bio‑Rad) and Technology (Certara) rounding out the remainder. The story isn’t sector; it’s the risk gradient inside a single sector.

Within therapeutics, Deerfield is nudging weight from early, highly binary names toward later‑stage, somewhat de‑risked platforms. Big adds to Genmab, BioMarin, IDEAYA, and Mineralys come alongside trims in Cogent, Sionna, and several smaller, more speculative programs. You can see the same pattern in structured bets like TYRA: they’re willing to average down, but only in platforms they think have durable optionality.

They’re also ever so slightly upgrading the earnings quality of the book. New money into Boston Scientific, plus existing positions in Centene, Brookdale, and Envista, tilt a bit more capital toward recurring cash flows and procedures volume, away from pure trial readouts. Meanwhile, the solitary tech name, Certara, is gently reduced, underscoring that the edge here is drug and device picking, not software multiples.

Three years of roughly 40.0% annualized performance don’t happen by accident; they happen when a manager is willing to sell its own winners and reload uncomfortable names. This quarter shows Deerfield in exactly that mode: crystallizing gains in Cogent, Indivior, and other successes to build meaningful stakes in the next wave of late‑stage and commercializing assets.

Maintaining Nuvalent at 22.22% after a massive gain tells you they still see real runway in that core oncology platform, but the absence of incremental buying says position size is now the limiting factor. New and scaled positions in Genmab, IDEAYA, BioMarin, Mineralys, and Boston Scientific suggest a forward book geared to steady clinical catalysts and incrementally better earnings visibility, not a blind chase of early‑stage lottery tickets.

For observers, the signal is clear: Deerfield is migrating the portfolio from a cluster of maturing small/mid‑cap biotech trades toward a barbell of dominant winners and increasingly de‑risked pipelines. If history is any guide, the names they’re quietly stuffing with $50M–$100M tickets this quarter are the ones they expect to carry the next leg of that track record.